Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Decitabine may improve CAR-T efficacy in refractory/relapsed acute leukemia patients carrying TP53 alterations

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Kenderian SS, Porter DL, Gill S. Chimeric antigen receptor T cells and hematopoietic cell transplantation: how not to put the CART before the horse. Biol Blood Marrow Transplant 2017;23:235–46.

    CAS  Article  Google Scholar 

  2. 2.

    Pan J, Tan Y, Deng B, Tong C, Hua L, Ling Z, et al. Frequent occurrence of CD19-negative relapse after CD19 CAR T and consolidation therapy in 14 TP53-mutated r/r B-ALL children. Leukemia. 2020;34(12):3382–87.

    Article  Google Scholar 

  3. 3.

    Pan J, Yang JF, Deng BP, Zhao XJ, Zhang X, Lin YH, et al. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients. Leukemia. 2017;31:2587–93.

    CAS  Article  Google Scholar 

  4. 4.

    Qu C, Li Z, Kang L, Wang Y, Dai H, Yin J, et al. Successful treatment of two relapsed/refractory t(8;21) acute myeloid leukemia patients by CD19-directed chimeric antigen receptor T cells. Bone Marrow Transplant. 2019;54:1138–40.

    CAS  Article  Google Scholar 

  5. 5.

    Li S, Xue L, Wang M, Qiang P, Xu H, Zhang X, et al. Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma. OncoTargets Ther. 2019;12:5627–38.

    CAS  Article  Google Scholar 

  6. 6.

    Ghoneim HE, Fan Y, Moustaki A, Abdelsamed HA, Dash P, Dogra P, et al. De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation. Cell. 2017;170:142–57.e19.

    CAS  Article  Google Scholar 

  7. 7.

    Valdez BC, Tang X, Li Y, Murray D, Liu Y, Popat U, et al. Epigenetic modification enhances the cytotoxicity of busulfan and4-hydroperoxycyclophosphamide in AML cells. Exp Hematol. 2018;67:49–59.e1.

    CAS  Article  Google Scholar 

  8. 8.

    Pusic I, Choi J, Fiala MA, Gao F, Holt M, Cashen AF, et al. Maintenance therapy with decitabine after allogeneic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 2015;21:1761–9.

    CAS  Article  Google Scholar 

  9. 9.

    Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5:177ra138.

    Article  Google Scholar 

  10. 10.

    Hu Y, Wu Z, Luo Y, Shi J, Yu J, Pu C, et al. Potent anti-leukemia activities of chimeric antigen receptor-modified T cells against CD19 in chinese patients with relapsed/refractory acute lymphocytic leukemia. Clin Cancer Res. 2017;23:3297–306.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

We would like to thank Dr. Robert Gale for reviewing our paper. We also thank all members of the study team, the patient, and their family. This work was supported by research grants from National Natural Science Foundation of China (81873443 and 81400155), National Science and Technology Major Project (2017ZX09304021), National Key R&D Program of China (2016YFC0902800), Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), Frontier Clinical Technical Project of the Science and Technology Department of Jiangsu Province (BE2017655), Jiangsu Provincial Medical Talent (ZDRCA2016045), Jiangsu Natural Science Foundation of China (BK20140374), Top-notch Young Health Talents, 5th Suzhou Health Professionals Program (GSWS2019035), Major Natural Science Research Projects in institutions of higher education of Jiangsu Province (19KJA210002), and the Key Science Research Project of Jiangsu Commission of Health (K2019022).

Author information

Affiliations

Authors

Corresponding author

Correspondence to Xiaowen Tang.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Qu, C., Song, Y., Yin, J. et al. Decitabine may improve CAR-T efficacy in refractory/relapsed acute leukemia patients carrying TP53 alterations. Bone Marrow Transplant (2021). https://doi.org/10.1038/s41409-021-01230-z

Download citation

Search

Quick links